ConductScience.org, home

Paper4771975

Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.

Dombernowsky P and 1 other. Acta Pathol Microbiol Scand A, 1973. Cited by 170 papers, by iCite.

Cite this record

ConductScience Library. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Papers, record 4771975. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4771975

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.
PubMed
Journal
Acta Pathol Microbiol Scand A
PubMed
Year
1973
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
170
iCite
Relative citation ratio, by iCite
5.3
iCite
Revised in PubMed
2019-10-30
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dombernowsky PP
2Nissen NIN I

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia L1210Major topic
PodophyllotoxinMajor topic
Animals
Drug Evaluation, Preclinical
Female
Injections, Intraperitoneal
Male
Mice
Neoplasm Transplantation
Time Factors
Transplantation, Homologous

Source PubMed

Download CSV of topics

Cited by37

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 170 citations.

PMIDTitleJournalYearIn PapersSource
33921719Podophyllotoxin: History, Recent Advances and Future Prospects.Biomolecules2021https://conductscience.org/library/papers/33921719PubMed
22993597Inhibition of tumor angiogenesis by oral etoposide.Exp Ther Med2010https://conductscience.org/library/papers/22993597PubMed
15356657Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse.Leukemia2004https://conductscience.org/library/papers/15356657PubMed
15139794Pharmacokinetic optimisation of treatment with oral etoposide.Clin Pharmacokinet2004https://conductscience.org/library/papers/15139794PubMed
10711842Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues.Drugs1999https://conductscience.org/library/papers/10711842PubMed
9667675Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.Br J Cancer1998https://conductscience.org/library/papers/9667675PubMed
8609070Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer.Jpn J Cancer Res1996https://conductscience.org/library/papers/8609070PubMed
8174207Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8174207PubMed
8137464Chronic oral etoposide in advanced breast cancer.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8137464PubMed
8075006Multilevel therapeutic targeting by topoisomerase inhibitors.Br J Cancer Suppl1994https://conductscience.org/library/papers/8075006PubMed
8070033Schedule-dependent topoisomerase II-inhibiting drugs.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8070033PubMed
8070031Etoposide dosage and pharmacodynamics.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8070031PubMed
8070017Prolonged administration of low-daily-dose etoposide: a superior dosing schedule?Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8070017PubMed
7947097Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.Br J Cancer1994https://conductscience.org/library/papers/7947097PubMed
7781140Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7781140PubMed
7554043Etoposide protein binding in cancer patients.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7554043PubMed
7539339Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7539339PubMed
7083457A phase I trial of continuous infusion VP16-213 (etoposide).Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7083457PubMed
7044594VP16-213 (etoposide). A critical review of its activity.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044594PubMed
7031350[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].Klin Wochenschr1981https://conductscience.org/library/papers/7031350PubMed

See all 37 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4771975

GET https://conductscience.org/api/papers/v1/4771975/cited_by?page=2